Patients with KRAS+ NSCLC and bone metastases had a significantly higher RANKL expression and higher RANKL: OPG ratio (p=0.002) compared to patients with KRAS+ NSCLC without bone metastases (p=0.017). The gene discussed is TNFRSF11B; the disease is non-small cell lung carcinoma.